The "sledgehammer-like treatment" of stem cell transplants had no benefit for most mantle cell lymphoma patients, according ...

Late-breaking research reveals there is no benefit from high-dose chemotherapy followed by autologous stem cell transplant ...

Late-breaking research reveals there is no benefit from high-dose chemotherapy followed by autologous stem cell transplant ...

Late-breaking research finds no survival benefit from autologous stem cell transplant in mantle cell lymphoma patients with ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN DIEGO -- Patients with mantle cell lymphoma (MCL) and undetectable minimal residual disease (uMRD) after induction ...

Late-breaking research reveals there is no benefit from high-dose chemotherapy followed by autologous stem cell transplant (ASCT) for patients with mantle cell lymphoma (MCL) in remission following ...

Autologous stem cell transplant plus Rituxan did not improve survival outcomes in certain patients with mantle cell lymphoma compared with Rituxan alone.

Hematology blood disorders are diseases that affect the blood and hematopoietic system’s functions. It includes leukemia, ...

Late-breaking research reveals there is no benefit from high-dose chemotherapy followed by autologous stem cell transplant ...

By studying mutations in malignant T cells that cause lymphoma, they zeroed ... How Gene Activity Modulates the Amount of Immune Cell Production in Mice Jan. 26, 2024 — Researchers describe how ...

The analysis pooled data from ongoing phase 1/2 clinical studies evaluating DZD8586 in patients with B-NHL who had progressed following, or were intolerant to, prior systemic therapies. As of October ...